SCHEMBL96898

SCHEMBL96898

CCCCc1ccccc1CCCC=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
LIPG Q9Y5X9 1/20 0.43
TRPV1 Q8NER1 2/20 0.42
FAAH O00519 2/20 0.42
THRA P10827 1/20 0.40
THRB P10828 1/20 0.40
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
BID P55957 3/20 0.38
BCL2L1 Q07817 3/20 0.38
MCL1 Q07820 3/20 0.38
BAK1 Q16611 3/20 0.38
MMP2 P08253 2/20 0.38
F7 P08709 2/20 0.38
F3 P13726 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3345733 0.92 TSHR (0.44) TSHRCYP3A4CYP2D6CYP2C9LIPG
SCHEMBL30845912 0.92 TSHR (0.44) TSHRCYP3A4CYP2D6CYP2C9LIPG
SCHEMBL5599488 0.90 TSHR (0.41) TSHRCYP3A4CYP2D6CYP2C9LIPG
Propionaldehyde SCHEMBL29282081 0.89 CYP3A4 (0.41) TSHRCYP3A4CYP2D6CYP2C9LIPG
Butanal SCHEMBL4564980 0.88 CYP3A4 (0.40) TSHRCYP3A4CYP2D6CYP2C9LIPG
SCHEMBL3693829 0.86 LIPG (0.50) TSHRLIPGTRPV1THRATHRB
Pentanal SCHEMBL29110702 0.85 TSHR (0.48) TSHRCYP3A4CYP2D6CYP2C9LIPG
SCHEMBL28437315 0.85 LIPG (0.53) TSHRLIPGTRPV1FAAHTHRA
SCHEMBL20339544 0.84 CYP3A4 (0.44) CYP3A4CYP2D6CYP2C9LIPGTHRA
SCHEMBL29520482 0.82 LIPG (0.56) CYP3A4CYP2D6CYP2C9LIPGNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
CN-101068810-B Carbostyril compound OTSUKA PHARMA CO LTD 2011-02-09 CN disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
CN-101068810-A Carbostyril compound OTSUKA PHARMA CO LTD (JP) 2007-11-07 CN disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB TSHR 3439/4885CYP3A4 3412/4885CYP2D6 3834/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 TSHR 110/4885CYP3A4 953/4885CYP2D6 1754/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 TSHR 110/4885CYP3A4 953/4885CYP2D6 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.